Ftse Mib
35.145,72
0,11%
DAX
20.311,29
-0,03%
S&P 500
5.918,25
0,16%
NASDAQ
19.478,88
-0,06%
Bitcoin
93.450,11
-1,69%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ BriaCell Therapeutics Corporation (BCTXW) BriaCell Therapeutics Corporation (BCTXW) Notizie

BriaCell Therapeutics Corporation

BCTXW
0,1802
0,00 (0,00%)
09 Gen 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Warrant Azionario
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
17/12/202422:05GLOBEBriaCell Announces Availability of Annual General Meeting..
17/12/202422:05EDGAR2Form DEF 14A - Other definitive proxy statements
17/12/202422:05GLOBEBriaPro Therapeutics Corp. Announces Availability of Annual..
16/12/202422:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
16/12/202422:05EDGAR2Form 8-K - Current report
13/12/202422:15EDGAR2Form 8-K - Current report
13/12/202422:05GLOBEBriaCell Therapeutics Announces Closing of $5.5 Million..
13/12/202413:50GLOBEBriaCell 2024 SABCS® Poster Highlights Ability of Bria-IMT™..
12/12/202423:27EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
12/12/202412:06EDGAR2Form SC 13D/A - General Statement of Acquisition of..
12/12/202405:54GLOBEBriaCell Therapeutics Announces Pricing of $5.5 Million..
11/12/202423:21EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
11/12/202422:05GLOBEBriaCell Therapeutics Announces Proposed Public Offering
11/12/202413:50GLOBEBriaCell Presents Unprecedented Overall Survival Data in..
10/12/202412:06EDGAR2Form SC 13D/A - General Statement of Acquisition of..
05/12/202413:45EDGAR2Form SC 13D/A - General Statement of Acquisition of..
02/12/202413:50GLOBEBriaCell Receives Green-Light from Data Safety Monitoring..
26/11/202413:50GLOBEBriaCell 2024 SABCS® Spotlight Poster to Showcase Positive..
25/11/202422:00EDGAR2Form 8-K - Current report
25/11/202413:50GLOBEBriaCell Provides Update to its Board of Directors
21/11/202413:50GLOBEBriaCell Announces First Patient Dosed with Bria-OTS™ in..
14/11/202418:17EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
08/11/202413:50GLOBEBriaCell Showcases Robust Anti-Cancer Activity of..
04/11/202413:50GLOBEBriaCell Overall Survival Data Selected for Spotlight Poster..
01/11/202421:05EDGAR2Form 8-K - Current report
22/10/202413:50GLOBEBriaCell Reports Outperforming Metastatic Breast Cancer..
15/10/202413:50GLOBEBriaCell Provides Phase 3 Clinical Engagement Update in..
02/10/202422:30EDGAR2Form 8-K - Current report
02/10/202422:05GLOBEBriaCell Therapeutics Announces Closing of $5 Million..
02/10/202416:12EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
01/10/202422:02EDGAR2Form 8-K - Current report
01/10/202420:05GLOBEBriaCell Therapeutics Announces $5 Million Offering
01/10/202413:50GLOBEBriaCell Reports 100% Resolution of Brain Metastasis in..
18/9/202413:50GLOBEBriaCell Announces FDA-Authorized Expanded Access Policy for..
16/9/202416:22EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
12/9/202422:25EDGAR2Form 8-K - Current report
12/9/202422:05GLOBEBriaCell Therapeutics Announces Closing of $8.5 Million..
11/9/202418:09GLOBEBriaCell Therapeutics Announces $8.5 Million Offering
11/9/202414:50EDGAR2Form 8-K - Current report
11/9/202413:50GLOBEBriaCell Reports Positive Overall Survival (OS) in..
10/9/202413:50GLOBEBriaCell Announces Positive Pre-IND Meeting with FDA for..
09/9/202413:50GLOBEBriaCell Announces Presentation at the 2024 Society for..
18/7/202413:56GLOBEBriaCell Quadruples Progression Free Survival (PFS) in..
14/6/202422:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/6/202422:05EDGAR2Form 8-K - Current report
03/6/202414:00GLOBEBriaCell Presents Clinical Efficacy Data at ASCO 2024
30/5/202414:00GLOBEBriaCell Initiates Patient Enrollment in First-in-Human..
28/5/202414:00GLOBEBriaCell Announces Clinical Supply Agreement with BeiGene..
24/5/202414:58EDGAR2Form SC 13D/A - General statement of acquisition of..
24/5/202414:00GLOBEBriaCell Doubles Progression-Free-Survival (PFS) and Reports..
Apertura: Min: Max:
Chiusura: 0,1802

La tua Cronologia

NASDAQ
BCTXW
BriaCell Therapeutics
LSE
0RIM
Gensight Biologics
BIT
P1TXJ4
BNP Paribas Issuance
LSE
0TXW
Perseus Mining
BOV
AMAR3Q
LOJAS MARISA ON
BIT
NSCIT0054170
Lanterna Mortgage
BOV
AVGO34R
Broadcom
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network